OmniAb (OABI)
NASDAQ:OABI
Want to see OABI full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.11Last Year’s EPS
-0.15Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong positive operational and commercial momentum: a large YoY revenue surge driven by partner milestones, multiple clinical advancements (including OmnidAb entrants and a Phase III progression), improved operating efficiencies, raised revenue guidance, healthy technology traction (xPloration and OmniUltra) and a solid near-term cash balance. Offsetting items include a $2.9M noncash impairment that increased GAAP expense guidance, continued reliance on lumpy milestone revenue rather than royalties, ongoing net losses, and projected year-end cash decline. Overall, the positive operational and revenue developments and guidance raise materially outweigh the lowlights, though risks from milestone variability and funding remain.Company Guidance
Strong Quarter Revenue Growth
Total revenue of $14.4M in Q1 2026 versus $4.2M in Q1 2025, an increase of approximately 243%, driven primarily by higher milestone revenue from partner clinical progress.
Raised Full-Year 2026 Revenue Guidance
Company raised 2026 revenue outlook to $28M–$33M after an unexpected partner milestone in Q1, signaling greater line-of-sight into milestone upside.
Clinical Pipeline Advancement
32 active clinical programs/approved products; two OmnidAb-derived programs entered human trials in Q1 (one now in Phase II); Ramantamig moved from Phase I to Phase III; approximately $350M in remaining potential contracted milestones tied to clinical-stage programs.
Large Contracted Milestone and Royalty Base
Over $3.0B in total contracted milestones across portfolio with an average contracted royalty rate of ~3.4%; ~98% of active programs include contracted future economics to OmniAb.
Operating Efficiency and Expense Reductions
GAAP operating expenses decreased slightly to $22.3M from $23.0M year-over-year; R&D down $3.0M to $9.6M and G&A down $1.3M to $6.6M. New cash operating expense metric showed a larger decline when removing noncash items.
Improved Profitability Metrics (Smaller Loss)
Net loss narrowed to $7.7M ($0.06 per share) in Q1 2026 versus $18.2M ($0.17) in Q1 2025, a reduction in net loss of ~$10.5M (~58% improvement). Excluding the one-time noncash charge, EPS loss would have been $0.04.
Solid Cash Position and Updated Year-End Cash Guidance
Cash and equivalents of $49.1M at quarter end. With raised revenue outlook and unchanged cash operating expense guidance, projected year-end cash of $33M–$38M.
Technology and Commercial Momentum
xPloration single B-cell platform building a growing sales funnel and demos; OmniUltra (launched Dec) and OmnidAb showing early commercial traction (OmnidAb has programs in clinic). Company partners include 8 of the top 10 pharma companies.
OABI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
OABI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $1.47 | $1.66 | +12.93% |
Mar 04, 2026 | $1.81 | $2.00 | +10.50% |
Nov 04, 2025 | $1.48 | $1.42 | -4.05% |
Aug 06, 2025 | $1.93 | $1.88 | -2.59% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does OmniAb (OABI) report earnings?
OmniAb (OABI) is schdueled to report earning on Aug 06, 2026, TBA (Confirmed).
What is OmniAb (OABI) earnings time?
OmniAb (OABI) earnings time is at Aug 06, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is OABI EPS forecast?
OABI EPS forecast for the fiscal quarter 2026 (Q2) is -0.11.